GMAT Question of the Day - Daily to your Mailbox; hard ones only

 It is currently 14 Aug 2018, 14:59

GMAT Club Daily Prep

Thank you for using the timer - this advanced tool can estimate your performance and suggest more practice questions. We have subscribed you to Daily Prep Questions via email.

Customized
for You

we will pick new questions that match your level based on your Timer History

Track

every week, we’ll send you an estimated GMAT score based on your performance

Practice
Pays

we will pick new questions that match your level based on your Timer History

In clinical trials of new medicines, half of the subjects receive

Author Message
TAGS:

Hide Tags

Senior CR Moderator
Status: Long way to go!
Joined: 10 Oct 2016
Posts: 1394
Location: Viet Nam
In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

20 Sep 2017, 02:52
3
00:00

Difficulty:

95% (hard)

Question Stats:

45% (01:21) correct 55% (01:43) wrong based on 365 sessions

HideShow timer Statistics

In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteers

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Source: LSAT

_________________
Intern
Joined: 23 Feb 2017
Posts: 37
Re: In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

20 Sep 2017, 03:01
1
I am with A.. answer choice should pose some concern on the experiment itself if we don't know who is using placebo and who is using medication..

Sent from my XT1575 using GMAT Club Forum mobile app
Intern
Joined: 17 Jun 2008
Posts: 12
Re: In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

20 Sep 2017, 03:14
IMO A

B - As per this choice even the subjects given Placebo will show improvement as do the subjects given drug being tested. Therefore in such cases the experimenters will not clearly find out which subjects are actually being given the drug tested.
C - Subject being healthy volunteers is not relevant to the argument.
D - Duration of the trail is not relevant to the argument.
E - Requirements of the law is not relevant to the argument.
Manager
Joined: 30 Jan 2017
Posts: 86
Location: India
Schools: ISB '19
GMAT 1: 630 Q47 V29
GMAT 2: 660 Q47 V34
GMAT 3: 730 Q49 V40
GPA: 3.9
Re: In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

12 Oct 2017, 02:49
2
broall wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteers

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Source: LSAT

The intent of using placebo is that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. Now, what if by some means the experimenters are able to differentiate between the two kind of subject (with and without placebo) ? Will the experimenters be frustrated ? Yes. That's the exact situation we are looking for.

Option A says that the experimenters know about the side effects of the drug being tested. Now, if the subjects start showing these exact side-effects, the experimenters will easily identify the subjects to whom the actual drug is administered.

Hence, this situation will frustrate the experimenters and Option A is our answer !!
Intern
Joined: 23 Jul 2012
Posts: 25
Location: United States
Concentration: Entrepreneurship, Strategy
GMAT 1: 640 Q49 V27
GMAT 2: 690 Q50 V33
GMAT 3: 700 Q50 V34
GMAT 4: 740 Q50 V39
GRE 1: Q800 V630
GPA: 3.08
WE: Research (Pharmaceuticals and Biotech)
Re: In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

18 Oct 2017, 18:03
IMO A is the correct answer. Only this suggests that the experimenters will be able to know which group is on which medicine. Hence, the frustration.
Verbal Forum Moderator
Status: Greatness begins beyond your comfort zone
Joined: 08 Dec 2013
Posts: 2105
Location: India
Concentration: General Management, Strategy
Schools: Kelley '20, ISB '19
GPA: 3.2
WE: Information Technology (Consulting)
Re: In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

12 Dec 2017, 11:50
1
broall wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteers

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Source: LSAT

Half will receive the drug that is being tested.

These clinical trials are designed so that BOTH the experimenters and subjects will be not know which group received the real drug.

The last statement begins with the word "however," so we can expect some sort of caveat or contrast with what we have read.

It's like "we try to live in this perfect idealized theoretical word where we do this and that. However..."

This however states that the intention is basically muddled because of something.

I would say this is a resolve the paradox/discrepancy type of question.

A) This would complete the explanation as to why those intentions would be muddled! If it is true that sometimes the subjects that receive the real drug start developing symptoms that experimenters recognize as being side effects from that drug.

For example, lets say they want to drug a new workout drug to see how it works with weight loss. Lets say they include in this a chemical that is known to cause acne breakouts. The experimenters do not know which group was given the drug, however, once people start breaking out, this situation of who knows what can now be considered muddled.

B) This would be consistent with the experimenters not knowing which group received the placebo and which received the real drug.

C) Out of scope. We do not know what the intentions of these trials are.

D) Does not change the implications of whether or not those experimenters who started from the beginning now know which group received the placebo and which received the real drug.

E) This is applied to both groups. The experimenters will not know which group received the placebo and which received the real drug.
_________________

When everything seems to be going against you, remember that the airplane takes off against the wind, not with it. - Henry Ford
The Moment You Think About Giving Up, Think Of The Reason Why You Held On So Long
+1 Kudos if you find this post helpful

BSchool Forum Moderator
Joined: 28 Mar 2017
Posts: 1095
Location: India
Concentration: Finance, Technology
GMAT 1: 730 Q49 V41
GPA: 4
Re: In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

12 Dec 2017, 13:17
broall wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteers

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Source: LSAT

Hello broall,

How can the intention be frustrated? This phrase just took me aback. Whatever i understood from the passage just didn't seem to be consistent with this particular line.
The source of frustration can be anything and i really don't understand how the intent can become frustrated.

Please throw some light on this. Because of this final line i just got mixed up between A and B because I couldn't exactly pin point the source of frustration.

Regards
_________________

Kudos if my post helps!

Long And A Fruitful Journey - V21 to V41; If I can, So Can You!!

Preparing for RC my way

My study resources:
1. Useful Formulae, Concepts and Tricks-Quant
2. e-GMAT's ALL SC Compilation
3. LSAT RC compilation
4. Actual LSAT CR collection by Broal
5. QOTD RC (Carcass)
6. Challange OG RC
7. GMAT Prep Challenge RC

Senior CR Moderator
Status: Long way to go!
Joined: 10 Oct 2016
Posts: 1394
Location: Viet Nam
In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

12 Dec 2017, 19:03
gmatexam439 wrote:
broall wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteers

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Source: LSAT

Hello broall,

How can the intention be frustrated? This phrase just took me aback. Whatever i understood from the passage just didn't seem to be consistent with this particular line.
The source of frustration can be anything and i really don't understand how the intent can become frustrated.

Please throw some light on this. Because of this final line i just got mixed up between A and B because I couldn't exactly pin point the source of frustration.

Regards

Refer to fmik7894's comment. The improtant information is in 2nd sentence.
_________________
BSchool Forum Moderator
Joined: 28 Mar 2017
Posts: 1095
Location: India
Concentration: Finance, Technology
GMAT 1: 730 Q49 V41
GPA: 4
Re: In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

14 Dec 2017, 02:16
Manager
Joined: 27 Dec 2016
Posts: 232
Concentration: Marketing, Social Entrepreneurship
GPA: 3.65
WE: Marketing (Education)
Re: In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

20 Dec 2017, 00:42
broall wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or not

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteers

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusion

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placebo

Source: LSAT

This is a double-blind experiment, for achieving the result that experimenters will NOT find out which subjects are actually being given the drug being tested.

I chose B, but I realized that A is correct. Experimenters will be frustrated because the reality will be revealed easily by the symptoms.

Great question!
_________________

There's an app for that - Steve Jobs.

Intern
Joined: 24 Oct 2016
Posts: 46
Location: India
GMAT 1: 710 Q49 V38
GPA: 3.61
In clinical trials of new medicines, half of the subjects receive  [#permalink]

Show Tags

29 May 2018, 23:43
broall wrote:
In clinical trials of new medicines, half of the subjects receive the drug being tested and half receive a physiologically inert substance—a placebo. Trials are designed with the intention that neither subjects nor experimenters will find out which subjects are actually being given the drug being tested. However, this intention is frequently frustrated
because __________.

Which one of the following, if true, most appropriately completes the explanation?

(A) often the subjects who receive the drug being tested develop symptoms that the experimenters recognize as side effects of the physiologically active drug Ah..yes this may be frustrating for the experimenters as they would know the drug caused the side effects and hence the subjects who received it.

(B) subjects who believe they are receiving the drug being tested often display improvements in their conditions regardless of whether what is administered to them is physiologically active or notOpposite answer. That's a good reason why subjects wouldn’t be disclosed to the experimenters. So why would it be frustrating?:)

(C) in general, when the trial is intended to establish the experimental drug’s safety rather than its effectiveness, all of the subjects are healthy volunteersWhy would it then be frustrating for both the parties?

(D) when a trial runs a long time, few of the experimenters will work on it from inception to conclusionFew or more experimenters stay till the end does not explain why non -disclosure is frustrating for them

(E) the people who are subjects for clinical trials must, by law, be volunteers and must be informed of the possibility that they will receive a placeboYes, this shouldn't be frustrating for the experimenters or the subjects since if someone knows that MAY receive a placebo does not reveal who ACTUALLY did receive one.

Source: LSAT

In clinical trials of new medicines, half of the subjects receive &nbs [#permalink] 29 May 2018, 23:43
Display posts from previous: Sort by

Events & Promotions

 Powered by phpBB © phpBB Group | Emoji artwork provided by EmojiOne Kindly note that the GMAT® test is a registered trademark of the Graduate Management Admission Council®, and this site has neither been reviewed nor endorsed by GMAC®.